These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19057270)

  • 1. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.
    Kubota K; Nishiwaki Y; Tamura T; Nakagawa K; Matsui K; Watanabe K; Hida T; Kawahara M; Katakami N; Takeda K; Yokoyama A; Noda K; Fukuoka M; Saijo N
    J Thorac Oncol; 2008 Dec; 3(12):1439-45. PubMed ID: 19057270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
    J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
    Mok T; Wu YL; Au JS; Zhou C; Zhang L; Perng RP; Park K
    J Thorac Oncol; 2010 Oct; 5(10):1609-15. PubMed ID: 20808255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).
    Nakagawa K; Kudoh S; Ohe Y; Johkoh T; Ando M; Yamazaki N; Seki A; Takemoto S; Fukuoka M
    J Thorac Oncol; 2012 Aug; 7(8):1296-303. PubMed ID: 22610257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.
    Uhm JE; Park BB; Ahn MJ; Lee J; Ahn JS; Kim SW; Kim HT; Lee JS; Kang JH; Cho JY; Song HS; Park SH; Sohn CH; Shin SW; Choi JH; Park K
    J Thorac Oncol; 2009 Sep; 4(9):1136-43. PubMed ID: 19687764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
    Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
    J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803).
    Yamada K; Takayama K; Kawakami S; Saruwatari K; Morinaga R; Harada T; Aragane N; Nagata S; Kishimoto J; Nakanishi Y; Ichinose Y
    Jpn J Clin Oncol; 2013 Jun; 43(6):629-35. PubMed ID: 23599349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
    Akerley W; Boucher KM; Bentz JS; Arbogast K; Walters T
    J Thorac Oncol; 2009 Feb; 4(2):214-9. PubMed ID: 19179899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.
    Mazzoni F; Rotella V; Pratesi N; Boni L; Simi L; Orlando C; Comin CE; Maddau C; Di Costanzo F
    Tumori; 2011; 97(2):160-5. PubMed ID: 21617709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.
    Huang Y; Zhang L; Shi Y; Ma S; Liao M; Bai C; Zhang Q; Wang C; Luo F; Yu S; Qin S; Zhi X; Zhou C
    Jpn J Clin Oncol; 2015 Jun; 45(6):569-75. PubMed ID: 25855621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
    Tang CH; Liu XQ; Gao HJ; Li JJ; Guo WF; Li XY; Wang WX; Liu B; Qu LL; Wang WW
    Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):143-7. PubMed ID: 20403247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.
    Park K; Yu CJ; Kim SW; Lin MC; Sriuranpong V; Tsai CM; Lee JS; Kang JH; Chan KC; Perez-Moreno P; Button P; Ahn MJ; Mok T
    JAMA Oncol; 2016 Mar; 2(3):305-12. PubMed ID: 26720423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
    Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status.
    Aydiner A; Yildiz I; Seyidova A
    Asian Pac J Cancer Prev; 2013; 14(5):3255-61. PubMed ID: 23803112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
    Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Takahashi T; Yamamoto N; Nukiwa T; Mori K; Tsuboi M; Horai T; Masuda N; Eguchi K; Mitsudomi T; Yokota S; Segawa Y; Ichinose Y; Fukuoka M; Saijo N
    Anticancer Res; 2010 Feb; 30(2):557-63. PubMed ID: 20332470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
    Ranson M; Reck M; Anthoney A; Hanauske AR; Dean E; Melezinek I; Klingelschmitt G; Kletzl H; Blatter J; Twelves C
    Ann Oncol; 2010 Nov; 21(11):2233-2239. PubMed ID: 20444843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
    Tarhini AA; Rafique I; Floros T; Tran P; Gooding WE; Villaruz LC; Burns TF; Friedland DM; Petro DP; Farooqui M; Gomez-Garcia J; Gaither-Davis A; Dacic S; Argiris A; Socinski MA; Stabile LP; Siegfried JM
    Cancer; 2017 Aug; 123(15):2936-2944. PubMed ID: 28472537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.